Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

被引：0
|
作者：
Strauss, A. [1 ]
Heinrich, D. [2 ]
Parker, C. [3 ,4 ]
Shan, M. [5 ]
Wilhelm, S. [5 ]
Garcia-Vargas, J. [5 ]
O'Bryan-Tear, C. G. [6 ]
Sartor, O. [7 ]
机构：
[1] Univ Med Gottingen, Urol Klin, Gottingen, Germany
[2] Akershus Univ Hosp, Lorenskog, Norway
[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[4] Inst Canc Res, Sutton, Surrey, England
[5] Bayer Healthcare, Whippany, NJ USA
[6] Algeta ASA, Oslo, Norway
[7] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V553
引用
收藏
页码：177 / 178
页数：2
相关论文
共 50 条
  • [1] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [2] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
  • [3] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [4] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, G.
    Fang, F.
    Vogelzang, N. J.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [5] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
    Parker, Chris
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Fang, Fang
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [7] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [8] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: Baseline prognostic factor subgroup analysis
    O'Sullivan, J.
    Johannessen, D. C.
    Widmark, A.
    Syndikus, I.
    James, N.
    Dall'Oglio, M.
    Haugen, I.
    Cross, A.
    Garcia-Vargas, J.
    Vogelzang, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
  • [10] Hematologic safety of Ra-223 dichloride (Ra-223) in castration- resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Fang, F.
    Vogelzang, N. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 60
12345